The team behind this 8,500-sq-m single-use, monoclonal antibody biotech production facility for animal medication needed to meet its schedule targets so the owner could meet the earliest possible product-to-market date.
Transaction, set to close by third quarter next year, would create new public company with more than 53,000 employees, of which Jacobs shareholders would have a 63% ownership stake.
Energy and resilience megaprojects starting and planned in New York and New Jersey pose big logistical challenges but will generate economic and quality of life benefits, said public and private industry experts at Sept. 15 ENR forum in New York City.
Company says it will need more manufacturing plants to reach targeted EV battery production capacity, as a $4-billion electric vehicle battery assembly plant is advancing in De Soto, Kan.